Reducing Uncertainty
in the Care and Treatment of Blood Cancer
Reducing Uncertainty
in the Care and Treatment of Blood Cancer
Reducing Uncertainty
in the Care and Treatment of Blood Cancer
Test more accurately. More often.
Our proprietary novel droplet digital PCR assay enables personalized measurable residual disease detection for fusion-driven blood cancers.
Rapid Turnaround
Our streamlined sample processing and rapid analysis allow for fast, reliable results, helping you act quickly and confidently.
Exceptional Accuracy
Using ddPCR, we provide absolute oncogenic fusion quantification – down to 1 in 100,000 fusion transcripts – while maintaining an exceptionally low false-positive rate.
Low Cost
Our ddPCR-based assay eliminates the complex and expensive workflows associated with sequencing and flow cytometry, reducing costs while increasing accessibility.
Patent-pending Personalization
Personalized MRD testing targets each unique disease-defining gene fusion to ensure accurate monitoring of their disease.
Driven by expertise and innovatioN
Led by a team of dedicated oncologists and genomics specialists, we are committed to transforming blood cancer detection and enhancing patient care through sensitive, personalized MRD testing.
Driven by expertise and innovatioN
Led by a team of dedicated oncologists and genomics specialists, we are committed to transforming blood cancer detection and enhancing patient care through sensitive, personalized MRD testing.
Driven by expertise and innovatioN
Led by a team of dedicated oncologists and genomics specialists, we are committed to transforming blood cancer detection and enhancing patient care through sensitive, personalized MRD testing.
Our sensitive assays allow researchers to gauge therapeutic success long before traditional endpoints, shortening trial timelines and increasing confidence in new therapies.
Andrew Young, MD, PhD, Founder & CEO Pairidex
Our sensitive assays allow researchers to gauge therapeutic success long before traditional endpoints, shortening trial timelines and increasing confidence in new therapies.
Andrew Young, MD, PhD, Founder & CEO Pairidex
Our sensitive assays allow researchers to gauge therapeutic success long before traditional endpoints, shortening trial timelines and increasing confidence in new therapies.
Andrew Young, MD, PhD, Founder & CEO Pairidex
Connect with us
Looking to move the needle? Motivated to help? Let’s schedule a conversation.